Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Biogen (BIIB) Pushes Higher Following EPS
January 27, 2016 11:55 AM ESTBiogen (NASDAQ: BIIB) is pushing to the highs of the session following strong earnings and a solid outlook. Shares are now up 7.9%
... MoreBiogen (BIIB) Tops Q4 EPS by 42c; Guides In-Line
January 27, 2016 7:16 AM ESTBiogen (NASDAQ: BIIB) reported Q4 EPS of $4.50, $0.42 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.84 billion versus the consensus estimate of $2.71 billion.
GUIDANCE:
Biogen sees FY2016 EPS of $18.30-$18.60, versus the consensus of $18.45. Biogen sees FY2016 revenue of $11.1-11.3 billion, versus the consensus of $11.29 billion.
We saw solid performance in our industry leading multiple sclerosis portfolio and strong... More
